Multivariate analysis identified lower baseline fibrinogen (OR = 0.37, P = 0.001), higher body weight (OR = 1.05, P = 0.001), and lower prothrombin time (OR = 0.45, P = 0.008) as independent risk factors.<h4>Conclusion</h4>Hypofibrinogenemia was observed at a higher incidence (45.88%) in thyroid eye disease patients treated with tocilizumab. The gene discussed is F2; the disease is Hypofibrinogenemia.